fda warning letter glp-1 october 2025 issues first cGMP citing AI misuse in pharmaceutical manufacturing FDA Drug Recalls and Warnings:

Tirzepatide Semaglutide (Ozempic/Wegovy) activates GLP-1 receptors, which: Slows stomach emptying Reduces appetite Improves insulin sensitivity Typically results in 15-20% weight loss over a year Tirzepatide (Mounjaro/Zepbound) activates both GLP-1 and GIP receptors, which: Provides all semaglutide benefits May have stronger effects on glucose metabolism Often results in 20-25% weight loss over a year Sometimes has fewer gastrointestinal side effects Your optimal choice depends on your specific PCOS presentation

During the first week of treatment, some patients may start noticing mild appetite changes

The departments plan states that it will work toward issuing regulatory approval of a drug and publicplan recommendations on the same day for participating jurisdictions

The Drug Enforcement Administration does not classify it as a drug of abuse

Significant weight reduction was seen, but bone mineral density (BMD) did not change